Identification
- Generic Name
- Ethyl loflazepate
- DrugBank Accession Number
- DB01545
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Illicit
- Structure
Structure for Ethyl loflazepate (DB01545)
- Weight
- Average: 360.767
Monoisotopic: 360.067698236 - Chemical Formula
- C18H14ClFN2O3
- Synonyms
- Ethyl fluclozepate
- Ethyl loflazepate
- Ethylis loflazepas
- Loflazepate d'ethyle
- Loflazepato de etilo
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism AGABA(A) Receptor positive allosteric modulatorHumans AGABA(A) Receptor Benzodiazepine Binding Site ligandHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when Ethyl loflazepate is combined with 1,2-Benzodiazepine. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Ethyl loflazepate. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Ethyl loflazepate. Agomelatine The risk or severity of CNS depression can be increased when Ethyl loflazepate is combined with Agomelatine. Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Ethyl loflazepate. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Azutolem (Takata Seiyaku) / Bigson (Hyun Dai) / Medetax (Medisa Shinyaku) / Meilax (Meiji) / Ronlax (Shiono Kemikaru) / Sukarnase (Towa Yakuhin) / Victan (Sanofi-Aventis)
Categories
- ATC Codes
- N05BA18 — Ethyl loflazepate
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acid esters
- Alternative Parents
- 1,4-benzodiazepines / Fluorobenzenes / 1,3-dicarbonyl compounds / Aryl chlorides / Aryl fluorides / Secondary carboxylic acid amides / Carboxylic acid esters / Lactams / Ketimines / Propargyl-type 1,3-dipolar organic compounds show 7 more
- Substituents
- 1,3-dicarbonyl compound / 1,4-benzodiazepine / Alpha-amino acid ester / Aromatic heteropolycyclic compound / Aryl chloride / Aryl fluoride / Aryl halide / Azacycle / Benzenoid / Benzodiazepine show 24 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- VJB5FW9W9J
- CAS number
- 29177-84-2
- InChI Key
- CUCHJCMWNFEYOM-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H14ClFN2O3/c1-2-25-18(24)16-17(23)21-14-8-7-10(19)9-12(14)15(22-16)11-5-3-4-6-13(11)20/h3-9,16H,2H2,1H3,(H,21,23)
- IUPAC Name
- ethyl 7-chloro-5-(2-fluorophenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylate
- SMILES
- CCOC(=O)C1N=C(C2=CC=CC=C2F)C2=C(NC1=O)C=CC(Cl)=C2
References
- Synthesis Reference
British Patent 1,538,165.
- General References
- Not Available
- External Links
- KEGG Drug
- D01293
- PubChem Compound
- 3299
- PubChem Substance
- 46507486
- ChemSpider
- 3183
- 24524
- ChEBI
- 31573
- ChEMBL
- CHEMBL1213460
- Wikipedia
- Ethyl_loflazepate
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral 2.000 mg Tablet, film coated - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 196 British Patent 1,538,165. - Predicted Properties
Property Value Source Water Solubility 0.00525 mg/mL ALOGPS logP 3.36 ALOGPS logP 3.85 Chemaxon logS -4.8 ALOGPS pKa (Strongest Acidic) 9.49 Chemaxon pKa (Strongest Basic) -1.4 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 67.76 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 92.41 m3·mol-1 Chemaxon Polarizability 35.03 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9536 Caco-2 permeable + 0.5691 P-glycoprotein substrate Substrate 0.5 P-glycoprotein inhibitor I Non-inhibitor 0.6872 P-glycoprotein inhibitor II Non-inhibitor 0.9383 Renal organic cation transporter Non-inhibitor 0.8524 CYP450 2C9 substrate Non-substrate 0.7542 CYP450 2D6 substrate Non-substrate 0.8622 CYP450 3A4 substrate Substrate 0.5122 CYP450 1A2 substrate Inhibitor 0.7947 CYP450 2C9 inhibitor Non-inhibitor 0.5444 CYP450 2D6 inhibitor Non-inhibitor 0.9018 CYP450 2C19 inhibitor Inhibitor 0.6447 CYP450 3A4 inhibitor Non-inhibitor 0.7437 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5303 Ames test Non AMES toxic 0.6532 Carcinogenicity Non-carcinogens 0.6 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 1.5886 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9977 hERG inhibition (predictor II) Non-inhibitor 0.8853
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 179.02347 predictedDeepCCS 1.0 (2019) [M+H]+ 181.38147 predictedDeepCCS 1.0 (2019) [M+Na]+ 188.24712 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Positive allosteric modulator
- Curator comments
- The GABA(A) receptor is pentameric (i.e. comprising 5 subunit proteins) and therefore has a multitude of potential isoforms. The above target is a collection of all possible GABA(A) subunits that may participate in the formation of the pentameric receptor and is not meant to imply direct a drug-protein interaction for each individual subunit.
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Components:
References
- Sigel E, Steinmann ME: Structure, function, and modulation of GABA(A) receptors. J Biol Chem. 2012 Nov 23;287(48):40224-31. doi: 10.1074/jbc.R112.386664. Epub 2012 Oct 4. [Article]
- Zhu S, Noviello CM, Teng J, Walsh RM Jr, Kim JJ, Hibbs RE: Structure of a human synaptic GABAA receptor. Nature. 2018 Jul;559(7712):67-72. doi: 10.1038/s41586-018-0255-3. Epub 2018 Jun 27. [Article]
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Ligand
- Curator comments
- Benzodiazepines modulate GABA(A) function by binding at the interface between alpha (α) and gamma (γ) subunits. Of the 6 α-subunits, only 4 (α-1, -2, -3, and -5) participate in the formation of this binding site. The above target is a collection of all α- and γ-subunits that are known to participate in the formation of the benzodiazepine binding site.
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Components:
References
- Sigel E, Steinmann ME: Structure, function, and modulation of GABA(A) receptors. J Biol Chem. 2012 Nov 23;287(48):40224-31. doi: 10.1074/jbc.R112.386664. Epub 2012 Oct 4. [Article]
- Zhu S, Noviello CM, Teng J, Walsh RM Jr, Kim JJ, Hibbs RE: Structure of a human synaptic GABAA receptor. Nature. 2018 Jul;559(7712):67-72. doi: 10.1038/s41586-018-0255-3. Epub 2018 Jun 27. [Article]
Drug created at July 31, 2007 13:10 / Updated at March 04, 2021 09:26